Announcements Trials
Browse Landscape

Phase

Phase 1/2 4Phase 2 2Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Inflammatory Breast Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma of Lung 1

Interventions

Cyclophosphamide 517Bevacizumab 488Carboplatin 424pembrolizumab 387Paclitaxel 385Gemcitabine 372Cisplatin 366Docetaxel 323Rituximab 316Radiotherapy 296Nivolumab 247Doxorubicin 243Dexamethasone 240Fluorouracil 225Capecitabine 214Oxaliplatin 211Erlotinib Hydrochloride 206fludarabine phosphate 201Etoposide 188Cetuximab 186Lenalidomide 177Pemetrexed 176Bortezomib 174Trastuzumab 173Filgrastim 171fludarabine 166Prednisone 166Leucovorin 166Cytarabine 166Irinotecan 161

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Has results × bemcentinib × Clear all
NCT03184571 2025-09-25

Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

BerGenBio ASA

Phase 2 Completed
99 enrolled 20 charts
Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung

NCT03184558 2021-11-09

Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBC

BerGenBio ASA

Phase 2 Terminated
29 enrolled 10 charts
Breast

Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡